Efficacy and safety of empagliflozin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
- DOI
- 10.1016/j.clinre.2026.102898
- Published
- 2026 Aug 5
- Container
- Clinics and research in hepatology and gastroenterology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clinre.2026.102898,
title = {Efficacy and safety of empagliflozin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.},
author = {Samajdar SS and Joshi SR and Bhaduri G and Saboo B and Roy K and Mukherjee S and Bansode S and Bandyopadhyay S},
year = {2026},
journal = {Clinics and research in hepatology and gastroenterology},
doi = {10.1016/j.clinre.2026.102898},
url = {https://doi.org/10.1016/j.clinre.2026.102898}
}RIS
TY - JOUR TI - Efficacy and safety of empagliflozin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis. AU - Samajdar SS AU - Joshi SR AU - Bhaduri G AU - Saboo B AU - Roy K AU - Mukherjee S AU - Bansode S AU - Bandyopadhyay S PY - 2026 JO - Clinics and research in hepatology and gastroenterology DO - 10.1016/j.clinre.2026.102898 UR - https://doi.org/10.1016/j.clinre.2026.102898 ER -
APA
SS, S., SR, J., G, B., B, S., K, R., S, M., S, B., & S, B. (2026). Efficacy and safety of empagliflozin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.. Clinics and research in hepatology and gastroenterology. https://doi.org/10.1016/j.clinre.2026.102898
Source records
- pubmed · retrieved 2026-09-26T05:27:58.562Z
- europe-pmc · retrieved 2026-09-26T05:27:58.571Z